Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 5/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.48 |
| ▸ | ATR | Q13535 | 4/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125514 | 1.00 | PDCD1 (0.48) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL10125343 | 0.90 | PIK3CB (0.54) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10153952 | 0.90 | PDCD1 (0.49) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL9950095 | 0.89 | PDCD1 (0.49) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL10125225 | 0.89 | PDCD1 (0.49) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL9950090 | 0.89 | PDCD1 (0.49) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL13247962 | 0.88 | PDCD1 (0.53) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL10125222 | 0.88 | PDCD1 (0.53) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL9951135 | 0.87 | PDCD1 (0.47) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL9949986 | 0.87 | PDCD1 (0.47) | PDCD1CD274ATRCHEK1ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PDCD1 403/4885CD274 893/4885ATR 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.